Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 EUR | -.--% |
|
-36.71% | -79.47% |
01/05 | Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc. | CI |
12/04 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -30.07% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 3 | 100.0 % | -30.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 07/16/07 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 06/20/06 |
Bob Atwill
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 07/16/07 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 06/20/06 |
Ronald Barliant
BRD | Director/Board Member | 78 | 07/16/07 |
Rainer Boehm
BRD | Director/Board Member | 63 | 12/18/12 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 119,080,135 | 106,754,128 ( 89.65 %) | 0 | 89.65 % |
Company contact information
Humanigen, Inc.
830 Morris Turnpike 4th floor
07078, Essex County
+973 200 3100
http://www.humanigen.com![address Humanigen, Inc.(0KB2)](https://cdn.zonebourse.com/static/address/23175009.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+2.87% | 94.22B | |
-3.42% | 37.76B | |
-13.75% | 32.5B | |
+73.45% | 27.75B | |
-11.88% | 16.13B | |
+0.49% | 14.19B | |
-12.95% | 11.42B | |
+190.36% | 11.06B | |
-54.07% | 9.09B |
- Stock Market
- Equities
- HGENQ Stock
- 0KB2 Stock
- Company Humanigen, Inc.